461 related articles for article (PubMed ID: 25408518)
1. Dose finding with continuous outcome in phase I oncology trials.
Wang Y; Ivanova A
Pharm Stat; 2015; 14(2):102-7. PubMed ID: 25408518
[TBL] [Abstract][Full Text] [Related]
2. An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials.
Hirakawa A
Stat Med; 2012 Mar; 31(6):516-32. PubMed ID: 22108785
[TBL] [Abstract][Full Text] [Related]
3. Escalation with overdose control for phase I drug-combination trials.
Shi Y; Yin G
Stat Med; 2013 Nov; 32(25):4400-12. PubMed ID: 23630103
[TBL] [Abstract][Full Text] [Related]
4. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
Du Y; Yin J; Sargent DJ; Mandrekar SJ
J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
[TBL] [Abstract][Full Text] [Related]
5. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
[TBL] [Abstract][Full Text] [Related]
6. Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials.
Doussau A; Thiébaut R; Paoletti X
Stat Med; 2013 Dec; 32(30):5430-47. PubMed ID: 24018535
[TBL] [Abstract][Full Text] [Related]
7. A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles.
Yin J; Qin R; Ezzalfani M; Sargent DJ; Mandrekar SJ
Stat Med; 2017 Jan; 36(1):67-80. PubMed ID: 27633877
[TBL] [Abstract][Full Text] [Related]
8. A Bayesian dose finding design for dual endpoint phase I trials.
Loke YC; Tan SB; Cai Y; Machin D
Stat Med; 2006 Jan; 25(1):3-22. PubMed ID: 16013039
[TBL] [Abstract][Full Text] [Related]
9. Dose-finding designs in pediatric phase I clinical trials: comparison by simulations in a realistic timeline framework.
Doussau A; Asselain B; Le Deley MC; Geoerger B; Doz F; Vassal G; Paoletti X
Contemp Clin Trials; 2012 Jul; 33(4):657-65. PubMed ID: 22521954
[TBL] [Abstract][Full Text] [Related]
10. Small-sample behavior of novel phase I cancer trial designs.
Oron AP; Hoff PD
Clin Trials; 2013 Feb; 10(1):63-80. PubMed ID: 23345304
[TBL] [Abstract][Full Text] [Related]
11. Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities.
Ezzalfani M; Zohar S; Qin R; Mandrekar SJ; Deley MC
Stat Med; 2013 Jul; 32(16):2728-46. PubMed ID: 23335156
[TBL] [Abstract][Full Text] [Related]
12. Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.
Chen Z; Tighiouart M; Kowalski J
Contemp Clin Trials; 2012 Sep; 33(5):949-58. PubMed ID: 22561391
[TBL] [Abstract][Full Text] [Related]
13. Competing designs for drug combination in phase I dose-finding clinical trials.
Riviere MK; Dubois F; Zohar S
Stat Med; 2015 Jan; 34(1):1-12. PubMed ID: 24464821
[TBL] [Abstract][Full Text] [Related]
14. Bridging continual reassessment method for phase I clinical trials in different ethnic populations.
Liu S; Pan H; Xia J; Huang Q; Yuan Y
Stat Med; 2015 May; 34(10):1681-94. PubMed ID: 25626429
[TBL] [Abstract][Full Text] [Related]
15. A non-parametric approach to the design and analysis of two-dimensional dose-finding trials.
Ivanova A; Wang K
Stat Med; 2004 Jun; 23(12):1861-70. PubMed ID: 15195320
[TBL] [Abstract][Full Text] [Related]
16. Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control.
Tighiouart M; Rogatko A; Babb JS
Stat Med; 2005 Jul; 24(14):2183-96. PubMed ID: 15909291
[TBL] [Abstract][Full Text] [Related]
17. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
Paoletti X; Kramar A
Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
[TBL] [Abstract][Full Text] [Related]
18. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
Lin R; Yin G
Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
[TBL] [Abstract][Full Text] [Related]
19. Continuous toxicity monitoring in phase II trials in oncology.
Ivanova A; Qaqish BF; Schell MJ
Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
[TBL] [Abstract][Full Text] [Related]
20. A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials.
Hirakawa A; Hamada C; Matsui S
Stat Med; 2013 Nov; 32(26):4515-25. PubMed ID: 23650098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
